Clinical trials
Patient clinical trials
Below are recruiting patient clinical trials, each written for real people, not researchers. We’re tracking 14,861 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05371145RecruitingPhase 1/Phase 2
Carnosine study for people with blocked leg arteries
This Phase 1/2 study tests whether L-carnosine can improve symptoms or circulation in people with peripheral arterial disease (blocked arteries in the legs). You may be able to join if you’re in the right age range and have specific test results showing moderate artery blockage.
Louisville, KentuckyAges 50–80 - NCT05371756Recruiting
Bio sample collection study for people at risk of cancer
This study collects blood (and other biospecimens) to look for immune and molecular markers that may help explain cancer risk or response to treatment. If you’re an adult whose provider thinks you could develop cancer, or who has confirmed/suspected cancer, you may be asked for samples and consent to help researchers.
College Station, TexasAges 18 years+ - NCT05372718RecruitingPhase 3
Clot-busting drug versus surgery for sudden blocked leg arteries
This trial compares a clot-busting medicine (staphylokinase) against surgery in people with sudden, dangerous reduced blood flow to a leg. It may help find a safer or more effective way to restore circulation and prevent limb complications.
Kursk, Kursl RegionAges 18 years+ - NCT05372640RecruitingPhase 1
Drug combo trial for rare cancers with shared NUT features
This Phase 1 trial tests the safety and early signs of effectiveness of combining two anti-cancer drugs (ZEN003694 and abemaciclib) in teens and adults with metastatic or unresectable NUT carcinoma, breast cancer, and other solid tumors. It may help by finding a safer dose and whether the drug combination can shrink or control tumors that do not respond to standard treatments.
Los Angeles, CaliforniaAges 12 years+ - NCT05373940Recruiting
ICD placement to prevent sudden heart death in people over 70
This study looks at placing an ICD, a device that can stop dangerous heart rhythms, to help prevent sudden cardiac death. It is for people over 70 with specific heart function and heart failure symptoms.
Aix-en-ProvenceAges 70 years+ - NCT05375968RecruitingPhase 2
Test blood-flow changes in POTS after meals
This Phase 2 study looks at how blood pools in the belly veins when you stand or eat, in people with POTS (postural tachycardia syndrome). The goal is to understand what’s driving symptoms like feeling nearly faint and whether this helps guide better care.
Nashville, TennesseeAges 18–50 - NCT05376254Recruiting
3D heart scan study during LVAD implantation
This study uses special 3D heart imaging to better measure right-heart function during LVAD surgery. It may help doctors understand how the right side of the heart responds when a mechanical pump is put in.
Edmonton, AlbertaAges 16 years+ - NCT05376111RecruitingPhase 2
Venetoclax plus azacitidine for newly diagnosed T-ALL
This Phase 2 study tests whether venetoclax combined with azacitidine can treat newly diagnosed T-ALL, a type of leukemia. It may help reduce cancer activity and improve outcomes if you meet the safety and treatment timing requirements.
Suzhou, JiangsuAges 15 years+ - NCT05377034RecruitingPhase 2
Y-90 and immunotherapy vs Y-90 plus placebo for liver cancer
This phase 2 study tests whether adding immunotherapy drugs (atezolizumab and bevacizumab) after Y-90 treatment works better and is safe compared with Y-90 followed by placebo. It is for people with liver cancer that has not spread outside the liver but is difficult to treat.
BeijingAges 21–99 - NCT05378308Recruiting
Tracking blood thinner use in people with AF or blood clots
This registry study looks at how people with atrial fibrillation (AF) or blood clots (VTE) use blood thinners, especially NOACs, over time. It may help doctors better understand real-world patterns of treatment and outcomes.
Zhengzhou, HenanAges Any age - NCT05378204Recruiting
Testing DNA repair marker for PARP inhibitor resistance
This study looks at specific DNA “damage repair” proteins as a marker to understand why some BRCA-mutated breast cancers may resist PARP inhibitor treatment. Your biopsy (or existing biopsy) helps researchers study whether these lab markers relate to how well PARP inhibitors work.
BordeauxAges 18 years+ - NCT05378035Recruiting
DOAC interruption study for Chinese people with atrial fibrillation
This trial studies how safely and effectively to pause a blood thinner (a DOAC) for about 48 hours before an elective procedure in people with atrial fibrillation. It may help confirm the best way to reduce bleeding risk without raising stroke risk.
Hong KongAges 18–80 - NCT05378334Recruiting
Test herbal treatment for lung cancer spread to bone
This trial studies whether the herbal medicine HGXJT can improve outcomes and safety for people with non-small cell lung cancer that has spread to the bones. It is designed for a specific lung cancer type (EGFR and ALK wild type) and people who have not had certain immune treatments before.
Guangzhou, GuangdongAges 18–75 - NCT05378633Recruiting
CyberKnife treatment for multiple brain metastases
This trial looks at how well (and how much) CyberKnife radiation works for people with multiple brain metastases. It may help your care team understand the best way to treat several brain spots safely.
HeidelbergAges 18 years+ - NCT05379738Recruiting
Exercise program to aid recovery after donor stem cell transplant
This trial tests whether an adapted physical activity (tailored exercise) can help people recover after a donor stem cell transplant for blood cancers. If you’re able to participate, the program may support strength, well-being, and recovery during the transplant process.
NiceAges 18 years+ - NCT05379985RecruitingPhase 1/Phase 2
Test drug RMC-6236 for certain RAS mutations in advanced cancers
This trial tests whether RMC-6236 can treat advanced solid tumors that have specific RAS-related gene changes (especially certain KRAS G12 mutations). You may be able to join if your tumor’s DNA test shows the right mutation and your overall health is good enough for study visits.
Orange, CaliforniaAges 18 years+ - NCT05380414Recruiting
Study of advanced pancreatic cancer using tumor tissue profiles
This study looks at advanced or metastatic pancreatic cancer patients and uses stored tumor tissue to learn what may predict treatment outcomes. You may be able to join if you have had limited prior chemotherapy and can provide an archived tissue sample.
LyonAges 18 years+ - NCT05383963Recruiting
Using ICU routine data to diagnose sepsis sooner
This study checks whether information collected routinely in the ICU can help doctors recognize sepsis or septic shock earlier. If it works, it may improve how quickly diagnosis happens and potentially outcomes for patients.
BerlinAges 18 years+ - NCT05384288Recruiting
How kids with blood cancers respond to the flu vaccine
This study looks at how children with blood cancers respond to the seasonal flu shot. It may help doctors understand what protection the vaccine provides for pediatric oncology patients.
Memphis, TennesseeAges Up to 18 years - NCT05384691RecruitingPhase 2
Luspatercept for anemia in lower-risk MDS not needing transfusions
This Phase 2 trial studies whether luspatercept can improve anemia in people with lower-risk myelodysplastic syndrome (MDS) who do not currently need red-blood-cell transfusions. It’s also looking to see if the benefit is similar whether or not you have ring sideroblasts.
BerlinAges 18 years+ - NCT05384509Recruiting
Tracking antibody levels in cancer patients during COVID vaccines
This study measures COVID “neutralizing” antibodies over time in people with cancer who are on different kinds of cancer treatments. It aims to understand how vaccination and treatment type affect immune protection in cancer patients.
New Taipei CityAges 20 years+ - NCT05384392Recruiting
Blood and brain-marker study after a first psychotic episode
This study looks at whether special body and brain markers can predict how a person’s symptoms change over two years after a first psychotic episode. It may also help doctors understand who responds better to treatment, so future care can be more personalized.
AngersAges 15–30 - NCT05384873Recruiting
Immunonutrition to improve immunotherapy in metastatic lung cancer
This trial studies whether adding special nutrition (oral immunonutrition supplements) can help immunotherapy work better in people with metastatic non-small cell lung cancer. Participants receive immunotherapy, with or without chemotherapy, and must be able to take oral supplements.
PaviaAges 18 years+ - NCT05384626RecruitingPhase 1/Phase 2
Study of an ALK-targeted drug for ALK-positive lung cancer
This early-stage study tests neladalkib (NVL-655), a medicine designed to attack ALK-positive cancer. It may help people with advanced ALK-mutated or ALK-rearranged solid tumors, especially ALK-positive non-small cell lung cancer.
Orange, CaliforniaAges 12 years+
Hear when a new Patient trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for patient?
- Yes. Clin2 currently lists 14,861 recruiting patient studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a patient trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a patient trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.